ADORA2B: A Potential Drug Target and Biomarker (G136)

Target Name: ADORA2B

NCBI ID: G136

ADORA2B

Other Name(s): ADORA2 | adenosine A2b receptor | Adenosine receptor A2b | AA2BR_HUMAN | Adenosine A2b receptor

ADORA2B: A Potential Drug Target and Biomarker

ADORA2B, or adenosine monophosphate receptor A2B, is a protein that is expressed in the brain and plays a crucial role in the regulation of cardiovascular function. It is a G protein-coupled receptor (GPCR), which means it is a transmembrane protein that is connected to intracellular signaling pathways. ADORA2B is known for its role in modulating the rapid heartbeat that occurs after sexual stimulation, as well as its involvement in pain perception and anxiety.

Recent studies have suggested that ADORA2B may be a drug target for several diseases, including cardiovascular disease, pain, and anxiety disorders. This is because of its unique structure and the effects that have been observed when it is activated.

One of the potential benefits of targeting ADORA2B is its potential to block the effects of other GPCRs that are involved in pain and anxiety. This is because GPCRs are known to play a role in mediating pain and anxiety responses, and blocking them may be an effective way to treat these conditions. Additionally, because ADORA2B is involved in the regulation of cardiovascular function, targeting it may also be a way to treat cardiovascular disease.

Another potential benefit of targeting ADORA2B is its potential to block the effects of other GPCRs that are involved in sexual desire and motivation. This is because GPCRs are known to play a role in these processes, and blocking them may be an effective way to treat certain forms of sexual dysfunction.

In addition to its potential therapeutic benefits, ADORA2B is also a potential biomarker for several diseases. For example, it has been suggested that ADORA2B may be involved in the development of cardiovascular disease, and that its levels may be reduced in individuals with certain risk factors for this disease. Additionally, because ADORA2B is involved in the regulation of pain and anxiety, its levels may also be reduced in individuals with these conditions.

Targeting ADORA2B may also be a way to diagnose and monitor certain diseases. For example, the levels of ADORA2B have been shown to be reduced in individuals with certain forms of dementia, which may be an effective way to diagnose this disease. Additionally, because ADORA2B is involved in the regulation of cardiovascular function, targeting it may also be a way to monitor the effectiveness of certain treatments for cardiovascular disease.

In conclusion, ADORA2B is a protein that is involved in the regulation of cardiovascular function and has been shown to play a role in modulating pain and anxiety responses. As a result, targeting it may be an effective way to treat a variety of conditions, including cardiovascular disease, pain, and anxiety disorders. Additionally, because ADORA2B is a GPCR, targeting it may also be a way to block the effects of other GPCRs that are involved in pain and anxiety.

Protein Name: Adenosine A2b Receptor

Functions: Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase

The "ADORA2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADORA2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets